Abstract

DO.01.05

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

Jaissle G. B., Leitritz M., Gelisken F., Ziemssen F., Bartz-Schmidt K. U., Szurman P.
Universitäts-Augenklink, Department für Augenheilkunde, Eberhard-Karls-Universität Tübingen, Tübingen

Objective: To investigate the long-term effectiveness of intravitreal bevacizumab treatment in eyes with perfused macular edema due to branch retinal vein occlusion (BRVO).
Methods: In this prospective interventional case series, 23 consecutive, previously untreated eyes with perfused macular edema were treated with intravitreal bevacizumab (1.25 mg) injections and followed for one year. The main outcome measures were visual acuity (VA) and central retinal thickness (CRT). In addition, VA data were adapted to the non-logarithmic VA charts used in the previously published grid laser photocoagulation BRVO Study.
Results: The median VA gained 3.0 lines from baseline at 48 weeks. This was accompanied by a significant decrease by 39% of the median CRT. The mean number of re-injections was 1.6 during the first six months of follow-up and only 0.8 during the subsequent six months. In 65% of the cases, adapted VA data showed a gain of two or more lines and no eye lost more than one line.
Conclusions: Repetitive intravitreal bevacizumab injections result in a significant long-term improvement of VA and CRT. The number of re-injections necessary to maintain this effect declined over time. However, the treatment seems to be only slightly better than grid laser photocoagulation.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.